William Blair analyst Myles Minter has maintained their bullish stance on ARGX stock, giving a Buy rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors including Argenx’s strong financial performance and promising growth prospects. The company reported a significant revenue increase from its Vyvgart products, surpassing both the firm’s and market expectations. This impressive performance was driven by increased utilization and strategic pricing adjustments, particularly in the U.S. market.
Minter also noted the company’s consistent profitability, marking its fourth consecutive profitable quarter, which has contributed to a robust cash position. Additionally, Argenx’s Vyvgart remains a leading choice in its therapeutic category, further supporting the Buy rating. These factors collectively highlight Argenx’s strong market position and potential for continued growth.
In another report released on July 28, Piper Sandler also maintained a Buy rating on the stock with a $750.00 price target.